{"id":9311,"date":"2026-05-21T05:34:00","date_gmt":"2026-05-21T03:34:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=59174604dd3524495fd5081a1eb64cc9"},"modified":"2026-05-21T05:34:00","modified_gmt":"2026-05-21T03:34:00","slug":"phoenix-and-raven-become-first-canadian-telehealth-platforms-to-offer-generic-semaglutide-direct-to-patients","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=9311","title":{"rendered":"Phoenix and Raven Become First Canadian Telehealth Platforms to Offer Generic Semaglutide Direct to Patients"},"content":{"rendered":"

\nEligible Canadians can now access Health Canada\u2013approved generic semaglutide directly, by prescription, starting at $124.99<\/i><\/p>

TORONTO--(BUSINESS WIRE)--Today, Phoenix<\/b><\/a> and Raven<\/b><\/a>, leading Canadian digital health providers, announced the launch of generic semaglutide for direct-to-patient access in Canada, making them the first telehealth platform in the country to bring this medication to customers. Phoenix and Raven are looking to set the new pricing for optimal access with orders starting at $124.99, delivered by prescription across Canada.<\/p><\/a><\/a>

\nThe launch follows Health Canada's<\/a> recent approval on April 28, 2026, making Canada the first G7 country to offer a generic semaglutide. With multiple generic manufacturers now authorized to supply the Canadian market, today's launch signals the beginning of a new era of accessibility for a medication that has fundamentally reshaped conversations about chronic disease, weight, and preventive health.<\/p>

\nDemand ahead of launch has been significant, with thousands of Canadians having registered interest through the platform's waitlist<\/a>. The generic semaglutide offered by Phoenix and Raven is supplied and distributed domestically.<\/p>

\n\"For a long time, the conversation around semaglutide in Canada was simple: most people couldn't get it, and those who could, often couldn't afford it. That changes today,\u201d says Dr. Mark Broussenko, Medical Director<\/b> at Phoenix and Raven.<\/p>

\n\u201cGeneric approval is a turning point, not just for this medication, but for how Canadians think about access to care. When effective, evidence-based treatment becomes accessible and affordable, that's not just good for individual patients, it has the potential to meaningfully shift outcomes on a national level. This is what progress in Canadian healthcare looks like, and we are proud that Phoenix and Raven are the first digital telehealth providers to offer generic semaglutide to patients.\"<\/p>

\nPhoenix and Raven are Canada\u2019s leading telehealth platforms providing trusted online medical care designed for both men and women\u2019s needs and lifestyle. Both platforms facilitate access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Semaglutide is available by prescription only, with eligibility determined by a licensed Canadian prescriber. Patients are encouraged to speak with their provider to find out if it\u2019s right for them. Visit phoenix.ca<\/a> and getraven.com<\/a> to learn more.<\/p>

\nABOUT PHOENIX & RAVEN<\/b><\/p>

\nPhoenix is Canada\u2019s leading digital health clinic for men, specializing in three areas of treatment \u2013 erectile dysfunction, weight loss, and hair loss. Phoenix also launched Raven, a telehealth platform built to support women through every stage of their health journey, tailored to their needs, including treatments for weight loss, and hair loss. Both platforms facilitate access to licensed Canadian prescribers, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit phoenix.ca<\/a> and getraven.com<\/a> to learn more.<\/p> Contacts<\/b>

\nMEDIA CONTACT\n\n<\/b>Kayla Moyes\nDirector of Corporate Communications, Talk Shop Media\nkayla.moyes@talkshopmedia.com<\/a>250-218-9276<\/p>","protected":false},"excerpt":{"rendered":"

Eligible Canadians can now access Health Canada\u2013approved generic semaglutide directly, by prescription, starting at $124.99TORONTO–(BUSINESS WIRE)–Today, Phoenix and Raven, leading Canadian digital health providers, announced the launch of generic s…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9311","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9311"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9311\/revisions"}],"predecessor-version":[{"id":9312,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/9311\/revisions\/9312"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}